| Recent innovations in peptide based targeted drug delivery to cancer cells Y Gilad, M Firer, G Gellerman Biomedicines 4 (2), 11, 2016 | 101 | 2016 |
| Drug combination in cancer treatment—From cocktails to conjugated combinations Y Gilad, G Gellerman, DM Lonard, BW O’malley Cancers 13 (4), 669, 2021 | 68 | 2021 |
| Synthesis, biological studies and molecular dynamics of new anticancer RGD-based peptide conjugates for targeted drug delivery Y Gilad, E Noy, H Senderowitz, A Albeck, MA Firer, G Gellerman Bioorganic & medicinal chemistry 24 (2), 294-303, 2016 | 59 | 2016 |
| Dual‐drug RGD conjugates provide enhanced cytotoxicity to melanoma and non‐small lung cancer cells Y Gilad, E Noy, H Senderowitz, A Albeck, MA Firer, G Gellerman Peptide Science 106 (2), 160-171, 2016 | 56 | 2016 |
| Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination Y Gilad, Y Eliaz, Y Yu, SJ Han, BW O’Malley, DM Lonard Scientific reports 9 (1), 15099, 2019 | 47 | 2019 |
| “Switch off/switch on” regulation of drug cytotoxicity by conjugation to a cell targeting peptide Y Gilad, MA Firer, A Rozovsky, E Ragozin, B Redko, A Albeck, ... European journal of medicinal chemistry 85, 139-146, 2014 | 28 | 2014 |
| Drug resistance to chlorambucil in murine B-cell leukemic cells is overcome by its conjugation to a targeting peptide G Gellerman, S Baskin, L Galia, Y Gilad, MA Firer Anti-cancer drugs 24 (2), 112-119, 2013 | 28 | 2013 |
| Synthesis of Novel Protected Nα(ω-Drug) Amino Acid Building Units for Facile Preparation of Anticancer Drug-Conjugates Y Gilad, S Waintraub, A Albeck, G Gellerman International Journal of Peptide Research and Therapeutics 22 (3), 301-316, 2016 | 11 | 2016 |
| A genome-scale CRISPR Cas9 dropout screen identifies synthetically lethal targets in SRC-3 inhibited cancer cells Y Gilad, Y Eliaz, Y Yu, AM Dean, SJ Han, L Qin, BW O’Malley, DM Lonard Communications Biology 4 (1), 399, 2021 | 10 | 2021 |
| A fast entry to the novel medicinally-important 9-anilinoacridine peptidyls by solid phase organic synthesis (SPOS) T Brider, Y Gilad, G Gellerman Tetrahedron letters 52 (28), 3640-3644, 2011 | 9 | 2011 |
| Steroid receptor coactivator 3 is a key modulator of regulatory T cell–mediated tumor evasion SJ Han, P Jain, Y Gilad, Y Xia, N Sung, MJ Park, AM Dean, RB Lanz, J Xu, ... Proceedings of the National Academy of Sciences 120 (23), e2221707120, 2023 | 8 | 2023 |
| Steroid Receptor Coactivators-Their Role in Immunity Y Gilad, DM Lonard, BW O'Malley Frontiers in Immunology 13, 2022 | 8 | 2022 |
| Discovery of potent molecular chimera (CM358) to treat human metastatic melanoma Y Gilad, H Tuchinsky, G Ben-David, R Minnes, A Gancz, H Senderowitz, ... European Journal of Medicinal Chemistry 138, 602-615, 2017 | 8 | 2017 |
| Steroid receptor coactivators in Treg and Th17 cell biology and function Y Gilad, O Shimon, SJ Han, DM Lonard, BW O’Malley Frontiers in Immunology 15, 1389041, 2024 | | 2024 |
| Reply to: Target expression is a relevant factor in synthetic lethal screens Y Gilad, Y Eliaz, Y Yu, AM Dean, SJ Han, L Qin, BW O’Malley, DM Lonard Communications Biology 5 (1), 836, 2022 | | 2022 |
| Targeting of src-3 in immune cells as an immunomodulatory therapeutic for the treatment of cancer CD Bert W O'malley, Sang Jun Han, David M Lonard, Bryan Nikolai, Prashi Jain ... US Patent App. 17/650,640, 2022 | | 2022 |
| Anticancer drug conjugates G Gellerman, Y Gilad, H Tuchinsky US Patent 11,007,271, 2021 | | 2021 |
